Aytu BioScience (AYTU) Names Richard Eisenstadt CFO
- Wall St gains on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer
April 5, 2021 8:01 AM EDTENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer. Mr. Eisenstadt is an accomplished pharmaceutical industry executive with more than 20 years of experience in leading finance and accounting operations, supporting clinical development and commercialization, and raising capital within the life sciences sector.
Mr. Eisenstadt replaces David Green who has stepped down as Chief Financial Officer as of March 31, 2021.
Mr. Eisenstadt most recently was Chief Financial Officer... More